- per protocol design, Salarius Pharmaceuticals Inc SLRX is voluntary Pause enrollment of new patients in the Company’s Phase 1/2 study of Secldemstat for the treatment of Ewing’s sarcoma and FET-rearranged sarcoma.
- Ewing’s sarcoma is a rare type of cancer that occurs in bones or the soft tissue around bones.
- The pause in enrollment of new patients is due to the death of a patient with metastatic FET-rearranged sarcoma, which was classified as a Suspected Unexpected Serious Adverse Event (SUSAR).
- Following review of the SUSAR and available information by the Company’s independent Clinical Trial Safety Review Committee, patients currently being treated with selidemstat may continue treatment after consultation with their physician.
- Salarius has shared the details of the SUSAR with the FDA and intends to further analyze the available data. Salarius plans to publish preliminary results from the sarcoma clinical trial later this year.
- In January, Salarius agreed to acquire a portfolio for oral degradation of small molecule cancer proteins DeuterRx LLC This includes a leading drug candidate Salarius has renamed SP-3164 (formerly DRX-164)..
- Price promotion: SLRX shares are down 26.6% to $3.67 during the premarket session last check Tuesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
